file,ref_number,ref_text,doi,doi_url,titleDoi,firstAuthDoi,author_similarity,title_similarity
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[1],National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2021.,10.1111/j.1759-7714.2010.00016.x,https://doi.org/10.1111/j.1759-7714.2010.00016.x,"Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009",Xu,2,93
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[2],"Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330-338.",10.1038/nrc1074,https://doi.org/10.1038/nrc1074,5-Fluorouracil: mechanisms of action and clinical strategies,Longley,100,100
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[3],"Van Cutsem, E., Cervantes, A., & Nordlinger, B. (2014). Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 25(suppl_3), iii1-iii9.",10.1093/annonc/mdu260,https://doi.org/10.1093/annonc/mdu260,"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Van Cutsem,100,100
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[4],"Le, D. T., Uram, J. N., & Wang, H. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine, 372(26), 2509-2520.",10.1056/nejmc1510353,https://doi.org/10.1056/nejmc1510353,PD-1 Blockade in Tumors with Mismatch-Repair Deficiency,,0,100
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[5],"Compton, C. C. (2006). Prognostic factors in cancer. In Prognostic Factors in Cancer (pp. 43-66). Wiley-Liss.",10.3816/ccc.2002.n.020,https://doi.org/10.3816/ccc.2002.n.020,Pathologic Prognostic Factors in the Recurrence of Rectal Cancer,Compton,100,62
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[6],"Jayne, D. G., Fook, S., & Loi, C. (2002). Peritoneal carcinomatosis from colorectal cancer. British Journal of Surgery, 89(12), 1545-1550.",10.1046/j.1365-2168.2002.02274.x,https://doi.org/10.1046/j.1365-2168.2002.02274.x,Peritoneal carcinomatosis from colorectal cancer,Jayne,100,100
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[7],"Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7-30.",10.3322/caac.21590,https://doi.org/10.3322/caac.21590,"Cancer statistics, 2020",Siegel,100,100
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_18,[8],"Franko, J., Shi, Q., & Meyers, J. P. (2012). Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. The Lancet Oncology, 17(12), 1709-1719.",10.1016/s1470-2045(16)30500-9,https://doi.org/10.1016/s1470-2045(16)30500-9,Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database,Franko,100,100
